Both LTA4H crystal complexes are classified as antagonists of LTA4H, therefore the 38 DCT-compounds that docked with both crystals of LTA4H (Table 1) potentially reduce asthma symptoms such as increased mucous and persistent airway inflammation, through blocking the conversion of LTA4 to LTB4 (PDB; Uniprot). Here, DCT is linked to asthma.